Embecta to Acquire Owen Mumford in £150M Deal, Expanding Drug Delivery and Chronic Care Portfolio

Embecta Corp., the New Jersey-based diabetes care technology company, has announced that it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited, a privately held UK-based medical device innovator, in a deal valued at up to £150 million. The move signals a significant strategic pivot for embecta, from a company historically rooted in insulin delivery to a broad-based medical supplies and drug delivery platform provider.¹

Under the terms of the agreement, embecta will pay an upfront cash sum of £100 million at closing, with up to an additional £50 million in performance-based payments tied to net sales of Owen Mumford’s Aidaptus next-generation auto-injector platform over the 3 years following close. The transaction is expected to close in embecta’s fiscal third quarter of 2026, pending regulatory approvals.¹

A Legacy Device Maker Joins a Growing Platform

Founded in 1952 and headquartered in Oxfordshire, UK, Owen Mumford is credited with the first plastic autoinjector, a development with lasting relevance to pharmacy practice. The company’s Aidaptus platform is designed around a single form factor and streamlined assembly process, features that could reduce manufacturing complexity and support the supply of both branded and generic injectable therapies.²

Beyond autoinjectors, Owen Mumford also markets a portfolio of medical devices spanning point-of-care testing, self-injection, and pelvic health—product categories with strong representation on pharmacy shelves and in specialty care settings.²

What It Means for Pharmacists

Although the deal is primarily a corporate transaction, its downstream implications for pharmacy practice are worth noting. Autoinjectors have become a critical delivery mechanism for some of the fastest-growing drug classes in modern medicine, including glucagon-like peptide-1 receptor agonists for obesity and diabetes, biologics for autoimmune conditions, and epinephrine devices for anaphylaxis.

Embecta CEO Dev Kurdikar highlighted the company’s ambition to serve patients across “obesity, diabetes, autoimmune diseases, and anaphylaxis markets,” reinforcing that the acquisition is not a niche play but a broad expansion into conditions that pharmacists routinely counsel patients on.¹

For pharmacies that dispense self-injectable therapies, familiarity with autoinjector design and function is increasingly part of the clinical role. Pharmacists who counsel patients on proper device technique—a demonstrated driver of adherence³—may benefit from staying attuned to how platforms such as Aidaptus are positioned as future pharmaceutical partnerships develop.

REFERENCES

1. embecta announces definitive agreement to acquire Owen Mumford Holdings Limited. News release. embecta. March 19, 2026. Accessed March 20, 2026. https://investors.embecta.com/news-releases/news-release-details/embecta-announces-definitive-agreement-acquire-owen-mumford
2. Innovators in healthcare. Owen Mumford. Accessed March 20, 2026. https://www.owenmumford.com/us/about-us
3. Farhana L, Rahayu FP, Sholihah S, Sweileh W, Abdulah R, Alfian SD. Effectiveness of pharmacist-led intervention on medication adherence in chronic diseases: a systematic review of randomized controlled trials. Patient Preef Adherence. 2025;19:2161-2178. doi:10.2147/PPA.S530503